<DOC>
	<DOCNO>NCT01450176</DOCNO>
	<brief_summary>The purpose study compare patient satisfaction Pataday ( Olopatadine hydrochloride 0.2 % ) one daily ( QD ) Bepreve ( Bepotastine besilate ophthalmic solution 1.5 % ) two time day ( BID ) .</brief_summary>
	<brief_title>Comparing Patient Satisfaction With Pataday Bepreve</brief_title>
	<detailed_description>5 week randomize study 15 subject use Pataday qd 2 week , 15 subject use Bepreve BID 2 week . Following one-week washout period , two group give opposite test article ( TA ) 2 week . Subjects complete daily diary regard effect drug see clinic 3 exam .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be male female subject racial/ethnic group . Be least 18 year age old . Have diagnosis allergic conjunctivitis active symptom , concurrent ocular allergy associate condition plan ocular surgery study period . Willing able return require visit follow instruction investigator staff . Able selfadminister test article ( TA ) caregiver available instill dose TA . If woman , capable become pregnant , agree pregnancy test perform screening ( must negative ) agree use medically acceptable form birth control ( intrauterine device , birth control pill , patch subcutaneous implant , condom , diaphragm , abstinence ) throughout study duration least one week prior one week completion study . Women consider capable become pregnant include female experience menarche experience menopause ( define amenorrhea great 12 consecutive month ) undergo successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) . Sign date inform consent form approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) . Be willing/able return require study visit , follow instruction study investigator his/her staff , complete return Screening Subject Diaries . Have know hypersensitivity BEPREVE PATADAY component . Are actively take steroid antihistamine study within 7 day prior enrol study . Are pregnant , plan become pregnant , nursing/lactating . Have know history alcohol drug abuse . Participated study investigational drug device within past 30 day prior enrol study . Have presence active ocular infection ( bacterial , viral fungal ) , positive history ocular herpetic infection , preauricular lymphadenopathy visit . Have significant illness { eg : autoimmune disease , severe cardiovascular disease ( include arrhythmia ) } Investigator feel could expect interfere subject 's safety study parameter and/or put subject anyh unnecessary risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>eye</keyword>
	<keyword>itch</keyword>
	<keyword>allergy</keyword>
</DOC>